Germany-based Boehringer Ingelheim yesterday announced the acquisition of Vira Therapeutics for €210m. Vira Therapeutics is a biotech based in Austria, focusing on the research for virus-based therapies for the treatment of cancer. Vira develops viruses which are then patented. These are harmless to the organism and are grown inside cancer cells, then they destroy the same cells and stimulate the immune system to enhance tumor control. The main asset of the acquired company is undoubtedly VSV-GP–Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)–which will be used in combination with immunotherapies developed by Boehringer Ingelheim’s Oncology division.
Vira Therapeutics was established in 2013 as a spin-out of the Medical University of Innsbruck, by Professor Dorothee von Laer and Dr. Ludwig Weiss.
(Source: Boehringer Ingelheim)